GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Sustained clinically significant improvement of visual acuity at 2.5 years of follow-up in LHON patients with less than 2 years of onset of visual loss prior to treatment
Confirmation of the favorable long-term safety profile of GS010

Paris, France, December 5, 2017, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported 2.5 years of follow-up data from its Phase I/II clinical trial with the Company’s gene therapy GS010 in patients with Leber Hereditary Optic Neuropathy (LHON). These results confirm long-term sustained gains in visual acuity 2.5 years after a single intravitreal injection of GS010, especially in subjects with less than 2 years of onset of vision loss.

Please find the full PDF press release attached

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: GenSight Biologics